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Past Achievements in the
Control of Onchocerciasis
Large-scale control of onchocerciasis
commenced over three decades ago, initial-
ly through the Onchocerciasis Control
Programme in West Africa (OCP, 1974–
2002), and more recently by the African
Programme for Onchocerciasis Control
(APOC, 1995–2010). The goals of OCP
were to eliminate onchocerciasis as a public
health problem and to mitigate its negative
impact on the social and economic develop-
mentofaffectedregions[1–3].Thestrategic
objective of APOC is to permanently pro-
tect the remaining 120 million peopleat risk
of this debilitating and disfiguring disease in
19 countries in Africa through the estab-
lishment of community-directed treatment
with ivermectin (CDTI) that is capable of
being sustained by the communities after
APOC financing has ended (Figures 1 and
2). The achievements made to date, first by
OCP and subsequently by APOC, are
summarised in Table 1.
The long-term support of onchocercia-
sis control, together with sustained politi-
cal commitment of national governments,
bilateral donors, and non-governmental
development organisations (NGDOs), is
a major, yet unheralded public health and
development success story in Africa. The
regional approach and the emphasis on
continued operational research were also
critical factors in the success of the OCP.
In addition, the contributions of OCP and
APOC to health systems development,
especially at the peripheral level, have
been emphasised as an example of how
disease programmes can strengthen re-
source-poor health systems [3,4]. The
contribution of a diverse group of stake-
holders to the success of the OCP and
APOC partnerships has recently been
reviewed [5]. In APOC, the collaboration
between NGDOs and the Ministries of
Health (through designated national oncho-
cerciasis task forces [NOTFs]) is contribut-
ingsome25%ofresourcestoonchocerciasis
control, assisting in national capacity build-
ing and in the implementation of APOC
projects. The national task forces will
continue to fulfil these functions and
obligations at the same level of commitment
up to at least 2015.
Clearly, OCP and APOC have demon-
strated that inter-country collaboration
can tackle a major public health problem.
Both programmes have secured long-term
funding for ivermectin treatment through
a public–private partnership, and have
succeeded in scaling up interventions by
gaining country commitment and mobilis-
ing community involvement [3]. Control
efforts have had a significant impact on
both public health and development
objectives in affected regions [2–5]. For
example, investments in onchocerciasis
control have one of the highest economic
rates of return among international de-
velopment initiatives: an estimated 15%–
20% (see Box 1). In addition, the successes
of OCP increased accessibility to fertile
land, which in turn enhanced agricultural
yields, led to elevated crop diversity,
improved human nutritional status, and
removed two significant public health
problems, namely onchocercal blindness
and skin disease [6]. Whilst the OCP itself
ended in 2002, activities continued in
special intervention zones (SIZ) where
there were unsatisfactory epidemiological
situations suggesting the potential for
recrudescence and results in 2002 that
were not compatible with the achievement
of the OCP objective. Areas in Benin,
Togo, Ghana, Guinea, and Sierra Leone
were selected as special intervention zones.
The major strategy involved delivery of
ivermectin, but in Togo and Benin aerial
larviciding was also employed.
From Vector Control to Mass
Drug Administration via
Community-Directed Treatment
with Ivermectin
Vector control using aerial application
of larvicides was the initial strategy of the
OCP, with the aim of interrupting oncho-
cerciasis transmission. It was hypothesised
that maintaining this control strategy for
14 years (initially it was considered that 20
years was necessary) would result in adult
onchocercal parasites dying out naturally
in the human hosts. This strategy was
successful in the central OCP area
(,1 million km
2) where onchocerciasis in-
fection and transmission were eliminated,
and where active control could cease and
be replaced by surveillance [2]. However,
in the APOC countries, vector control was
considered neither feasible nor cost-effec-
tive, except for a few small isolated foci in
East and Central Africa [7,8] where
criteria were established for financing of
vector control. The underlying rationale
was that the foci were isolated, and hence
there was no risk of reinvasion of adjacent
blackfly populations. These foci were in
Uganda (Itwara), Tanzania (Tukuyu), and
on Bioko island in Equatorial Guinea [7].
The current mainstay for the control of
onchocerciasis rests on mass drug admin-
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name Mectizan). Ivermectin was regis-
tered in 1987 and subsequently donated to
affected communities by Merck & Co.
Inc., providing a drug for disease in-
tervention that was applicable in all
endemic areas [9]. Ivermectin distribution
was first introduced in ex-OCP countries
[10]. Ivermectin is effective against the
microfilariae that cause the severe mani-
festations of the disease, and MDA of
ivermectin proved an effective strategy for
eliminating onchocerciasis as a public
health problem. The main limitation of
ivermectin is that it has little effect on the
adult worms that continue to produce
microfilariae, and hence re-treatment is
required at annual intervals. MDA of
ivermectin reduces but does not interrupt
transmission, at least not during the first
years of intervention, and annual treat-
ment needs to be continued for a long
period of time. In other words, APOC’s
objective was to establish ‘‘effective and
sustainable community-directed treatment
with ivermectin (CDTI) in all endemic
areas’’ [5,11].
The necessary duration of ivermectin
treatment has yet to be determined, and
likely depends on treatment coverage and
initial levels of endemicity. Two scenarios
emerge, namely (1) continued treatment in
the most endemic foci where transmission
cannot be interrupted, and (2) cessation of
treatment in less affected areas after pro-
longed treatment. Although the second
scenario is as yet hypothetical, it is currently
under evaluation to test its feasibility.
The overarching goal of APOC is to
establish sustainable CDTI in all countries
where onchocerciasis remains endemic.
APOC’s achievements have been sum-
marised before [7,8], but there have been
delays in implementation of CDTI
projects [3] due to problems in conflict
and post-conflict areas and the treatment
complications linked to onchocerciasis
and loasis co-endemicity. In areas of Loa
loa there is a risk of severe adverse events
in people treated with ivermectin who
have a high microfilaraemia of L. loa,
which can result in encephalopathy
[12,13]. This has been a major impedi-
ment to the expansion of APOC in
Central Africa. However, it is expected
that by 2007 CDTI projects will have been
launched in all areas in Africa where
onchocerciasis is, or has been, a public
health problem.
Working Group on the Future of
Onchocerciasis Control in Africa
Against the background outlined above,
and in the light of an external evaluation of
APOC in 2005, the Committee of Spon-
soring Agencies established a working
group in 2006, at the request of the
governing body of APOC at the 11th
meeting of the Joint Action Forum in Paris.
The working group was given a mandate to
reflect on past achievements and forth-
coming challenges and opportunities of
APOC and its partners, and to put forward
recommendations on the future of oncho-
cerciasis control in Africa. The full report
from the working group is available as
Supporting Information File Text S1. The
following points were emphasised.
First, through CDTI, APOC has
worked to eliminate onchocerciasis as
a public health problem, an effort that
has also mitigated the disease’s impact on
socio-economic development in affected
regions. In view of APOC’s success in
onchocerciasis control, any premature
closure of the programme would lead to
the loss of the many benefits derived and
to the deterioration of the CDTI in-
frastructure, which could also serve as an
effective platform for the delivery of other
health interventions that are needed by
many millions of the under-served and
poorest people in Africa, and that address
the millennium development goals.
Figure 1. Palpable Onchocercal Nodule.
doi:10.1371/journal.pntd.0000074.g001
Figure 2. Onchocercal Skin Disease.
doi:10.1371/journal.pntd.0000074.g002
Table 1. Achievements of OCP and APOC.
OCP Results (1974–2002) APOC Results (1996–2005)
N Infection and eye lesions prevented in 40 million
people in 11 countries
N 40 million people in 16 countries under regular
ivermectin treatment
N 600,000 cases of blindness prevented N 500,000 DALYs per year averted
N 25 million hectares of abandoned arable land
reclaimed for settlement and agricultural
production, capable of feeding 17 million
people annually
N 177,000 communities mobilised
N Workforce of 261,000 community distributors
trained and available for other programmes
N Economic rate of return of 20% N Economic rate of return of 17%
N US$7 per DALY averted
DALY, disability-affected life year.
doi:10.1371/journal.pntd.0000074.t001
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challenges for onchocerciasis control: (1)
how can an adequate treatment coverage
with ivermectin be established and sus-
tained in those African settings where
MDA is indicated?; (2) what are the means
to determine where and when treatment
can be stopped?; and (3) how does one
ensure effective surveillance in areas where
active control has come to an end?
Third, Africa needs to maintain the
gains made in controlling onchocerciasis
by both the OCP and APOC and to
continue to reduce the impact of the
disease as a pressing public health problem
and an impediment to social and econom-
ic advances. Much is being achieved by
sustainable country programmes, and
hence it is necessary to ensure long-term
sustainability through the following ap-
proaches: (1) Continued advocacy to
maintain commitment to onchocerciasis
control; (2) Monitoring and evaluation of
control programmes and support to post-
control surveillance; (3) Maintenance of
a core body of onchocerciasis experts to
provide a forum to exchange expertise and
experiences; and (4) Long-term financial
sustainability of onchocerciasis control.
The working group’s vision of APOC is
of an effective organisation that lacks strict
geographical boundaries and can address
the need for advocacy, technical assis-
tance, and continued support for oncho-
cerciasis control throughout endemic areas
of Africa. The group suggested that APOC
should promote innovation at the com-
munity level and ensure the sustainability
of onchocerciasis programmes through its
operational philosophy of CDTI, as well as
harnessing additional resources to assist
countries in co-implementation of other
health interventions where appropriate.
Control efforts will require the further
development and refinement of a flexible
approach where countries can call on
different levels of support from APOC
according to their capacity and accom-
plishments to date. We are not suggesting
that a regional onchocerciasis control
programme with an indefinite end point
be established. However, continued suc-
cess requires long-term coordinated sup-
port, continuity of that support, and
a careful definition of the roles and
responsibilities of different actors and
stakeholders.
A number of recommendations ema-
nated from the review process and these
are summarised in Box 1. Additional
recommendations were also put forward
as implicit or essential to achieve the
strategic recommendations. The group
Box 1. Strategic Recommendations
1. APOC’s main objective of establishing sustainable national oncho-
cerciasis programmes in all countries where needed should be
maintained and endorsed.
2. APOC’s operations should be extended to 2015 to enable it to fulfil
its original objectives.
N APOC should complete the establishment of CDTI projects in all countries.
N APOC should develop an exit strategy that includes effective long-term
support mechanisms for countries to provide the limited support to CDTI and
onchocerciasis surveillance necessary after the programme has come to an end.
3. APOC should develop the evidence base to determine when and
where ivermectin treatment can be stopped, and provide guidance to
countries on how to prepare for and evaluate cessation of treatment.
N The group emphasised that there is insufficient knowledge about when and
how mass treatment can be stopped.
N The group suggested that APOC develop a plan, including resource
requirements, to monitor progress in areas where cessation of ivermectin
treatment has occurred.
4. APOC should promote integration and co-implementation of
interventions with CDTI to provide multiple health benefits to large
populations.
N APOC should advocate for integration of CDTI into strengthened health
systems, and develop plans for facilitation, advocacy, and exchange of best
practices.
N APOC should encourage joint financing and advocacy for NTD partnerships.
N Partners should continue to strengthen operational research on co-imple-
mentation, and NTD partnership representatives should participate in the Joint
Action Forum to promote harmonisation of partnerships.
5. APOC’s mandate should be extended to include all onchocerciasis-
endemic countries in Africa where the epidemiological situation
requires sustainable CDTI.
N This will ensure continuity of support to special intervention zones and former
OCP countries where sustainable CDTI still needs to be established.
N The capacity of the Multi-Disease Surveillance Centre to fulfil its anticipated
role in relation to onchocerciasis surveillance should be strengthened.
6. Financial planning and fundraising for onchocerciasis control should
build on existing mechanisms and traditional donors, but should also
explore new funding opportunities, particularly those offered in the
context of NTDs.
N Financial planning and fundraising will need to take into account the need to
secure country commitments to stable funding to achieve sustainable country
programmes.
N Financial planning and fundraising should cover the essential activities of the
extension to 2015 to allow APOC to fulfil its core mandate and the additional
activities identified in the strategic overview.
N Plans for an exit strategy should include the costing of core regional functions
that will be necessary post-APOC, together with an overview of which partners
and actors may be able to take on these functions and the necessary resource
requirements.
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future of onchocerciasis control in Africa.
Conclusion
Onchocerciasis control in Africa since
1974 has been one of the most successful
health and development activities in terms
of public health achievement, partnership
development, sustained donor support,
and social and economic development.
The group reviewed the complex issues
related to onchocerciasis control, identify-
ing those which must be addressed over
the next decade. The landscape of in-
ternational health has changed much since
the inception of APOC in 1995. In recent
years, however, there has been a renewed
interest in and enhanced profile of ne-
glected tropical diseases (NTDs), and the
success of onchocerciasis control is recog-
nised as a contributing factor, as it is a cost-
effective intervention that addresses the
millennium development goals and builds
partnerships with stakeholders in the in-
ternational health community. Onchocer-
ciasis control would be greatly assisted if
there were a drug that killed adult worms
(a macrofilaricide), and research to this
end must continue.
APOC, the group concluded, needs to
be provided with the resources through its
traditional donor base to continue until
2015, not only using its CDTI approach to
achieve control of onchocerciasis, but
building on this strategy to deliver other
health interventions and scale up NTD
control. The challenge is to translate the
country commitment as expressed in the
Yaounde ´ Ministerial Declaration [14]
towards a sustainable and integrated
approach for surveillance and control
within strengthened health systems. As
with other disabling infections, onchocer-
ciasis is not always seen as a priority and
must compete with other higher profile
diseases for resources. However, its control
is regarded as one of the most cost-
effective and successful health and de-
velopment partnerships of recent decades
[15]. Further information on recent prog-
ress is summarised in the World Health
Organization’s Weekly Epidemiological
Record [16].
Supporting Information
Text S1 Full Report from the APOC
Working Group
Found at: doi:10.1371/journal.pntd.
0000074.s001 (0.67 MB PDF)
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